Fluicell AB (publ) (FLUI.ST)
Fluicell AB (publ) operates in the Biotechnology industry of the Healthcare sector, headquartered in Mölndal, VG, SE. The stock last traded at $29.60, down 2.31% on the session, giving a market capitalisation of $40.7M. Its beta of 2.01 implies it has historically moved more than the broad market.
Fluicell AB (publ) is a global provider of cutting-edge single-cell discovery platforms, catering to applications in biomedicine, drug development, and bioprinting. The company's product line includes the BioPen PRIME and BioPen FLEX microfluidic systems, engineered for precise localized solution delivery during single-cell experiments and for managing the chemical microenvironment of individual intact cells within tissue or cell cultures. Furthermore, Fluicell offers the Dynaflow Resolve system, a specialized platform for secondary ion channel screening that enables the measurement of various ion channel currents in a patch-clamp recording configuration. This Swedish company, headquartered in Gothenburg, was founded in 2012.
Fluicell AB (publ) is most often compared with the following Healthcare names: